-+ 0.00%
-+ 0.00%
-+ 0.00%

MINK THERAPEUTICS REPORTS THIRD QUARTER 2026 RESULTS, FIRST PRE-COMMERCIAL PRODUCT REVENUE FROM AGENT-797, RANDOMIZED ARDS TRIAL ADVANCING, AND ARPA-H SELECTION FOR DEPLOYABLE CELL THERAPIES

Reuters·11/11/2026 12:31:10